BridgeBio Pharma BBIO Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$166.56M+1.8% | -$194.64M+27.2% | -$184.94M-12.6% | -$183.76M-143% | -$169.61M-369% | ||
| $1.19M-7.6% | $1.44M+5.0% | $1.4M-9.1% | $1.32M-16.3% | $1.28M-19.5% | ||
| $33.24M+28.4% | $34.64M+15.0% | $35.26M+29.8% | $37.24M+73.6% | $25.88M+51.7% | ||
| $1.82M+12.2% | $1.45M-29.7% | —— | —— | $1.62M— | ||
| $65.78M-40.5% | $22.93M+440% | $39.65M+21,886% | —— | $110.54M-52.7% | ||
| $7.05M+121% | $1.95M— | $6.77M— | $13.39M— | $3.19M— | ||
| -$7.17M-141% | $17.53M— | —— | —— | $17.57M+396% | ||
| -$37.48M-93.5% | $19.81M+73.7% | $18.85M+35.0% | $3.73M-43.5% | -$19.36M-29.4% | ||
| $18.85M+3,770% | —— | —— | $22.26M+604% | $487K-85.4% | ||
| $4.62M+56.8% | $24.78M+129% | $26.42M+578% | $23.66M+14,155% | $2.95M+334% | ||
| -$306K-1,557% | $434K— | —— | $5.44M+53.7% | $21K+101% | ||
| -$2.38M+7.5% | -$1.95M-250% | -$2.99M— | -$3.92M— | -$2.57M-111% | ||
| -$18.28M-17.5% | $0— | $0— | $15.56M— | -$15.56M-291% | ||
| $1.47M+47.5% | $1.46M+47.2% | —— | —— | $994K— | ||
| $0+100% | $0— | $0— | $0— | -$21.16M+20.4% | ||
| -$1.85M-26.0% | -$1.79M-24.0% | -$1.64M-11.0% | -$1.65M-18.8% | -$1.47M+7.8% | ||
| -$197.28M+1.0% | -$56.42M+71.1% | -$109.57M+39.3% | -$80.68M— | -$199.24M+9.2% | ||
| $69K— | $33K-29.8% | $470K+243% | $594K+1,000% | $0-100% | ||
| $52.67M— | $17.32M-26.1% | —— | —— | $0-100% | ||
| $10M— | $0— | $2.3M— | $0— | $0-100% | ||
| $0-100% | $0-100% | $2.4M+50.5% | $4.5M+88.0% | $1.6M+100% | ||
| -$42.74M-2,579% | -$14.35M— | —— | -$13M-528% | -$1.6M-107% | ||
| $82.5M+70.9% | —— | —— | —— | $48.28M— | ||
| —— | —— | —— | —— | —— | ||
| $0-100% | —— | —— | —— | $459M-3.0% | ||
| $22.59M— | $0— | $0— | $0— | $0-100% | ||
| $0-100% | $600K— | —— | —— | $800K— | ||
| $4.07M+129% | $7.43M+429% | $3.03M+110% | $2M+14.5% | $1.78M-39.5% | ||
| —— | —— | —— | —— | —— | ||
| $549.89M+812% | —— | —— | $302.04M— | $60.33M-78.4% | ||
| $309.88M+321% | -$72.96M-126% | -$106M— | $208.36M+189% | -$140.5M-270% | ||
| $20.32M-12.7% | —— | $20.4M-30.1% | —— | $23.27M-34.1% | ||
| $1.82M+12.2% | $1.45M-29.7% | —— | —— | $1.62M— | ||
| —— | $0-100% | $0-100% | $0-100% | $0-100% | ||
| $2.16M-45.4% | $8.59M+454% | —— | —— | $3.95M— | ||
| -$18.28M-17.5% | -$21.03M-26.0% | -$15.83M-141% | -$20.19M-155% | -$15.56M— | ||
| $12.99M+2,124% | $6.82M— | $3.32M-60.4% | -$2.34M— | -$642K-106% | ||
| -$2.38M+7.5% | -$1.95M-250% | -$2.99M— | -$3.92M— | -$2.57M-111% | ||
| -$37.48M-93.5% | $19.81M+73.7% | $18.85M+35.0% | $3.73M-43.5% | -$19.36M-29.4% | ||
| -$1.85M-26.0% | -$1.79M-24.0% | -$1.64M-11.0% | -$1.65M-18.8% | -$1.47M+7.8% | ||
| $1.8M+213% | -$545K+72.3% | -$742K-154% | $1.76M+454% | -$1.59M-257% | ||
| $18.85M+3,770% | —— | —— | $22.26M+604% | $487K-85.4% | ||
| $39.87M+66.0% | $38.68M+366% | $36.41M— | $26.03M— | $24.02M— | ||
| $1.47M+47.5% | $1.46M+47.2% | —— | —— | $994K— | ||
| -$306K-1,557% | $434K— | —— | $5.44M+53.7% | $21K+101% | ||
| —— | $0— | $0— | $0— | $0— | ||
| $0-100% | $0-100% | $2.4M+50.5% | $4.5M+88.0% | $1.6M+100% | ||
| $10M— | $3M-87.4% | —— | —— | $0-100% | ||
| $11.29M+7,742% | $8.56M— | —— | —— | $144K— | ||
| $0-100% | $600K— | —— | —— | $800K— | ||
| $5.47M+68.9% | —— | $3.18M+48.6% | —— | $3.24M+36.9% | ||
| $12K-96.4% | $31K+520% | $12K-94.1% | -$337K— | $337K+381% | ||
| $431K— | —— | —— | —— | $0-100% | ||
| -$1.96M-137% | -$860K+21.8% | -$3.09M-10.9% | -$816K-1,033% | -$824K+55.6% | ||
| $0-100% | —— | —— | —— | $4.5M— | ||
| -$197.35M+0.9% | -$56.45M+71.1% | -$110.04M+39.1% | -$81.28M— | -$199.24M+9.5% | ||
| -$197.35M+0.9% | -$56.45M+71.1% | -$110.04M+39.1% | -$81.28M— | -$199.24M+9.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does BridgeBio Pharma generate?
- BridgeBio Pharma (BBIO) generated -$444.0M in operating cash flow over the trailing twelve months.
- What is BridgeBio Pharma's free cash flow?
- After $1.2M of capital expenditures, BridgeBio Pharma's free cash flow was -$445.1M over the trailing twelve months, up 44.0% year over year.
- Where does BridgeBio Pharma's cash flow data come from?
- Every line is extracted from BridgeBio Pharma's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
